Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.99M | 11.98M | 7.35M | 7.40M | 12.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.99M | 11.98M | 7.35M | 7.40M | 12.54M |
| Cost of Revenue | 24.55M | 24.55M | 32.71M | 32.72M | 35.11M |
| Gross Profit | -19.56M | -12.57M | -25.37M | -25.33M | -22.57M |
| SG&A Expenses | 13.72M | 13.67M | 12.87M | 12.94M | 13.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.42M | 37.86M | 35.61M | 35.11M | 44.43M |
| Operating Income | -31.43M | -25.88M | -28.27M | -27.71M | -31.89M |
| Income Before Tax | -27.26M | -24.54M | -27.31M | -23.89M | -28.28M |
| Income Tax Expenses | 786.00K | 630.00K | 289.00K | 243.00K | 255.00K |
| Earnings from Continuing Operations | -28.04 | -25.17 | -27.60 | -24.14 | -28.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.04M | -25.17M | -27.60M | -24.14M | -28.54M |
| EBIT | -31.43M | -25.88M | -28.27M | -27.71M | -31.89M |
| EBITDA | -31.00M | -25.41M | -27.71M | -27.11M | -31.26M |
| EPS Basic | -1.04 | -0.94 | -1.03 | -0.91 | -1.08 |
| Normalized Basic EPS | -0.66 | -0.48 | -0.64 | -0.56 | -0.67 |
| EPS Diluted | -1.04 | -0.94 | -1.03 | -0.91 | -1.08 |
| Normalized Diluted EPS | -0.66 | -0.48 | -0.64 | -0.56 | -0.67 |
| Average Basic Shares Outstanding | 107.43M | 107.33M | 107.23M | 106.68M | 106.14M |
| Average Diluted Shares Outstanding | 107.43M | 107.33M | 107.23M | 106.68M | 106.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |